Filing Flows › Cytek Biosciences (CTKB) › Q3 2026 › vs Q2 2026
Cytek Biosciences (CTKB) Q3 2026 vs Q2 2026 (quarter over quarter)
Cytek Biosciences's revenue rose $5.1M (+11%) from $48.1M in Q2 2026 to $53.2M in Q3 2026. The biggest changes: Product +$4.6M (+14%); Service +$484K (+3%).
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product | $37.2M | $32.6M | $4.6M | +14% |
| Service | $16.1M | $15.6M | $484K | +3% |
| Revenue | $53.2M | $48.1M | $5.1M | +11% |
| Other income, net | $1.5M | −$243K | $1.8M | — |
| Income tax benefit | $811K | −$515K | $1.3M | — |
| Net loss | $6.1M | $12.2M | −$6.1M | -50% |
| Costs & expenses | $61.7M | $60.3M | $1.4M | +2% |
| Operating costs | $61.7M | $59.5M | $2.1M | +4% |
| Cost of revenue | $22.0M | $19.8M | $2.2M | +11% |
| Research & development | $9.4M | $9.7M | −$386K | -4% |
| Sales & marketing | $11.9M | $13.2M | −$1.3M | -10% |
| General & admin | $18.4M | $16.8M | $1.5M | +9% |
| Operating cash sources | $11.4M | $6.0M | $5.4M | +91% |
| Depreciation & amortization | $2.1M | $2.0M | $104K | +5% |
| Share-based compensation | $4.9M | $5.3M | −$485K | -9% |
| Cash used in operations | $4.5M | −$1.4M | $5.8M | — |
| Net loss absorbed | $6.1M | $12.2M | −$6.1M | -50% |
| Working capital & other | $5.3M | −$6.2M | $11.5M | — |
Questions
How much did Cytek Biosciences's revenue grow quarter over quarter in Q3 2026?
Cytek Biosciences's revenue rose $5.1M (+11%) from $48.1M in Q2 2026 to $53.2M in Q3 2026.
What drove Cytek Biosciences's revenue change in Q3 2026?
Product +$4.6M (+14%); Service +$484K (+3%).